Strategic Funding SpliceBio recently secured a $135M Series B led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, indicating strong investor confidence and a potential for strategic partnerships or co-development opportunities with portfolio companies.

Global Partnerships Significant backers include UCB Ventures, Ysios Capital, NEA, Gilde Healthcare and Asabys Partners, suggesting a well-connected investor network that could facilitate introductions to large pharma and biotech collaborators for licensing, joint development, or distribution arrangements.

Therapies Focus The company is advancing protein splicing–based gene therapies (SB-007) targeting retinal and other genetic diseases, presenting opportunities to explore clinical collaboration, access to trial sites, and companion diagnostic or delivery technology partnerships.

Leadership & Talent Key hires include a Chief Medical Officer appointed in early 2024 and a Chief Development Officer added in 2023, signaling a maturing organization ready for late-stage development, potential advisory roles, and executive-level collaboration with CROs and clinical manufacturing partners.

Growth Capabilities With a Barcelona base, 51–200 employees, and a demonstrated capacity to raise capital, SpliceBio is positioned for expansion in Europe and beyond; opportunities exist for manufacturing scale partnerships, supply chain optimization, and investor-backed strategic alliances to accelerate their pipeline.